The Role Of Circulating Tumor DNA In Therapeutic Resistance

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Schwartz R, Schaffer AA. The evolution of tumour phylogenetics: principles and practice. Nat Rev Genet. 2017;18(4):213–229. doi:10.1038/nrg.2016.17028190876
   PubMed Web of Science ®Google Scholar
• Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–28. doi:10.1126/science.959840959840
   PubMed Web of Science ®Google Scholar
• Barrett MT, Lenkiewicz E, Evers L, et al. Clonal evolution and therapeutic resistance in solid tumors. Front Pharmacol. 2013;4:2. doi:10.3389/fphar.2013.0000223372550
   PubMed Web of Science ®Google Scholar
• von Bubnoff N. Liquid biopsy: approaches to dynamic genotyping in cancer. Oncol Res Treat. 2017;40(7–8):409–416. doi:10.1159/00047886428693026
   PubMed Web of Science ®Google Scholar
• Konig IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine? Eur Respir J. 2017;50(4):1700391. doi:10.1183/13993003.00391-201729051268
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038–1042. doi:10.1056/NEJM20010405344140211287973
   PubMed Web of Science ®Google Scholar
• Lovly CM, Salama AKS, Salgia R, Tumor heterogeneity and therapeutic resistance. Am Soc Clin Oncol Educ Book. 2016;(36):e585–e593. doi:10.1200/EDBK_15880827249771
   PubMedGoogle Scholar
• Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res. 2010;3(11):1361–1364. doi:10.1158/1940-6207.CAPR-10-0234
   PubMed Web of Science ®Google Scholar
• Welch DR. Tumor heterogeneity–a ‘contemporary concept’ founded on historical insights and predictions. Cancer Res. 2016;76(1):4–6. doi:10.1158/0008-5472.CAN-15-302426729788
   PubMed Web of Science ®Google Scholar
• Kruh GD. Introduction to resistance to anticancer agents. Oncogene. 2003;22(47):7262–7264. doi:10.1038/sj.onc.120693214576836
   PubMed Web of Science ®Google Scholar
• Grzywa TM, Paskal W, Wlodarski PK. Intratumor and intertumor heterogeneity in Melanoma. Transl Oncol. 2017;10(6):956–975. doi:10.1016/j.tranon.2017.09.00729078205
   PubMed Web of Science ®Google Scholar
• Andor N, Graham TA. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med. 2016;22(1):105–113.26618723
   PubMed Web of Science ®Google Scholar
• Islam S, Paek AL, Hammer M, et al. Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma. Oncotarget. 2018;9(89):35875–35890. doi:10.18632/oncotarget.v9i8930542505
   PubMedGoogle Scholar
• Goodall J, Mateo J, Yuan W, et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 2017;7(9):1006–1017. doi:10.1158/2159-8290.CD-17-026128450425
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi:10.1126/science.123512223539594
   PubMed Web of Science ®Google Scholar
• Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46(5):318–322. doi:10.1159/0002267402779946
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.11245480
   PubMed Web of Science ®Google Scholar
• Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18(1):114. doi:10.1186/s12943-019-1043-x31269959
   PubMed Web of Science ®Google Scholar
• Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110–1122. doi:10.1016/j.cell.2014.07.01325171411
   PubMed Web of Science ®Google Scholar
• Cai X, Janku F, Zhan Q, Fan JB. Accessing genetic information with liquid biopsies. Trends Genet. 2015;31(10):564–575. doi:10.1016/j.tig.2015.06.00126450339
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–1209. doi:10.1056/NEJMoa121326123484797
   PubMed Web of Science ®Google Scholar
• Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016;2(8):1014–1022. doi:10.1001/jamaoncol.2016.017327055085
   PubMed Web of Science ®Google Scholar
• Paweletz CP, Sacher AG, Raymond CK, et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res. 2016;22(4):915–922. doi:10.1158/1078-0432.CCR-15-1627-T26459174
   PubMed Web of Science ®Google Scholar
• Gremel G, Lee RJ, Girotti MR, et al. Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. Ann Oncol. 2016;27(10):1959–1965. doi:10.1093/annonc/mdw27827502704
   PubMed Web of Science ®Google Scholar
• Mohan S, Heitzer E, Ulz P, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 2014;10(3):e1004271. doi:10.1371/journal.pgen.100427124676216
   PubMed Web of Science ®Google Scholar
• Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–554. doi:10.1038/nm.351924705333
   PubMed Web of Science ®Google Scholar
• Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547–555. doi:10.1038/nbt.352027018799
   PubMed Web of Science ®Google Scholar
• Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(23):9530–9535. doi:10.1073/pnas.110542210821586637
   PubMed Web of Science ®Google Scholar
• Stahlberg A, Krzyzanowski PM, Jackson JB, Egyud M, Stein L, Godfrey TE. Simple, multiplexed, PCR-based barcoding of DNA enables sensitive mutation detection in liquid biopsies using sequencing. Nucleic Acids Res. 2016;44(11):e105. doi:10.1093/nar/gkw22427060140
   PubMed Web of Science ®Google Scholar
• Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012;13(10):679–692. doi:10.1038/nrg327022945394
   PubMed Web of Science ®Google Scholar
• Pisanic TR 2nd, Athamanolap P, Poh W, et al. DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies. Nucleic Acids Res. 2015;43(22):e154. doi:10.1093/nar/gkv79526304549
   PubMed Web of Science ®Google Scholar
• Ramirez M, Rajaram S, Steininger RJ, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun. 2016;7:10690. doi:10.1038/ncomms1069026891683
   PubMed Web of Science ®Google Scholar
• Sabnis AJ, Bivona TG. Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology. Trends Mol Med. 2019;25(3):185–197. doi:10.1016/j.molmed.2018.12.00930686761
   PubMed Web of Science ®Google Scholar
• Garraway LA, Janne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012;2(3):214–226. doi:10.1158/2159-8290.CD-12-001222585993
   PubMed Web of Science ®Google Scholar
• Esposito A, Criscitiello C, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacol Ther. 2016;157:120–124. doi:10.1016/j.pharmthera.2015.11.00726615782
   PubMed Web of Science ®Google Scholar
• Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–123. doi:10.1373/clinchem.2014.22267925388429
   PubMed Web of Science ®Google Scholar
• Spano JP, Lagorce C, Atlan D, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005;16(1):102–108. doi:10.1093/annonc/mdi00615598946
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–1634. doi:10.1200/JCO.2007.14.711618316791
   PubMed Web of Science ®Google Scholar
• Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med. 2011;154(1):37–49. doi:10.7326/0003-4819-154-1-201101040-0000621200037
   PubMed Web of Science ®Google Scholar
• Diaz Jr LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–540. doi:10.1038/nature1121922722843
   PubMed Web of Science ®Google Scholar
• Bronte G, Silvestris N, Castiglia M, et al. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Oncotarget. 2015;6(28):24780–24796.26318427
   PubMed Web of Science ®Google Scholar
• Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3(6):658–673. doi:10.1158/2159-8290.CD-12-055823729478
   PubMed Web of Science ®Google Scholar
• Xu JM, Wang Y, Wang YL, et al. PIK3CA mutations contribute to acquired cetuximab resistance in patients with metastatic colorectal cancer. Clin Cancer Res. 2017;23(16):4602–4616. doi:10.1158/1078-0432.CCR-16-273828424201
   PubMed Web of Science ®Google Scholar
• Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017;8(43):75712–75726. doi:10.18632/oncotarget.v8i4329088904
   PubMedGoogle Scholar
• Zheng D, Ye X, Zhang MZ, et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016;6:20913. doi:10.1038/srep2091326867973
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–1043. doi:10.1126/science.114147817463250
   PubMed Web of Science ®Google Scholar
• Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016;7:11815. doi:10.1038/ncomms1181527283993
   PubMed Web of Science ®Google Scholar
• Remon J, Caramella C, Jovelet C, et al. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Ann Oncol. 2017;28(4):784–790. doi:10.1093/annonc/mdx01728104619
   PubMed Web of Science ®Google Scholar
• Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC. A Phase II trial of osimertinib in the second-line treatment of non-small cell lung cancer with the EGFR T790M mutation, detected from circulating tumor DNA: liquidLung-O-cohort 2. Cancer Res Treat. 2018;51:777.30189719
   PubMed Web of Science ®Google Scholar
• Du J, Wu X, Tong X, et al. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification. Oncotarget. 2017;8(16):26281–26287. doi:10.18632/oncotarget.1545728460431
   PubMedGoogle Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. doi:10.1126/science.37981063798106
   PubMed Web of Science ®Google Scholar
• de Melo Gagliato D, Jardim DL, Marchesi MS, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016;7(39):64431–64446. doi:10.18632/oncotarget.704326824988
   PubMed Web of Science ®Google Scholar
• Ma F, Zhu W, Guan Y, et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget. 2016;7(40):66020–66031. doi:10.18632/oncotarget.v7i4027602761
   PubMedGoogle Scholar
• Page K, Guttery DS, Fernandez-Garcia D, et al. Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer. Clin Chem. 2017;63(2):532–541. doi:10.1373/clinchem.2016.26183427940449
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39. doi:10.1056/NEJMoa141269025399551
   PubMed Web of Science ®Google Scholar
• Long GV, Fung C, Menzies AM, et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 2014;5:5694. doi:10.1038/ncomms669425452114
   PubMed Web of Science ®Google Scholar
• Gray ES, Rizos H, Reid AL, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008–42018. doi:10.18632/oncotarget.v6i3926524482
   PubMedGoogle Scholar
• Oddo D, Sennott EM, Barault L, et al. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer. Cancer Res. 2016;76(15):4504–4515. doi:10.1158/0008-5472.CAN-16-039627312529
   PubMed Web of Science ®Google Scholar
• Wyatt AW, Azad AA, Volik SV, et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. 2016;2(12):1598–1606. doi:10.1001/jamaoncol.2016.049427148695
   PubMed Web of Science ®Google Scholar
• Beddowes E, Sammut SJ, Gao M, Caldas C. Predicting treatment resistance and relapse through circulating DNA. Breast. 2017;34 Suppl 1:S31–S35. doi:10.1016/j.breast.2017.06.02428694015
   PubMed Web of Science ®Google Scholar
• McCoach CE, Blakely CM, Banks KC, et al. Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clin Cancer Res. 2018;24(12):2758–2770. doi:10.1158/1078-0432.CCR-17-258829599410
   PubMed Web of Science ®Google Scholar
• Namlos HM, Boye K, Mishkin SJ, et al. Noninvasive detection of ctDNA reveals intratumor heterogeneity and is associated with tumor burden in gastrointestinal stromal tumor. Mol Cancer Ther. 2018;17(11):2473–2480. doi:10.1158/1535-7163.MCT-18-017430097488
   PubMed Web of Science ®Google Scholar
• Wada N, Kurokawa Y, Takahashi T, et al. Detecting secondary C-KIT mutations in the peripheral blood of patients with imatinib-resistant gastrointestinal stromal tumor. Oncology. 2016;90(2):112–117. doi:10.1159/00044294826779618
   PubMed Web of Science ®Google Scholar
• Horn L, Whisenant JG, Wakelee H, et al. Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. J Thoracic Oncol. 2019. doi:10.1016/j.jtho.2019.08.003
   Web of Science ®Google Scholar
• Lee B, Lipton L, Cohen J, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol. 2019;30(9):1472–1478. doi:10.1093/annonc/mdz20031250894
   PubMed Web of Science ®Google Scholar
• Fribbens C, Garcia Murillas I, Beaney M, et al. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann Oncol. 2018;29(1):145–153. doi:10.1093/annonc/mdx48329045530
   PubMed Web of Science ®Google Scholar
• Lin J, Ma L, Zhang D, et al. Tumour biomarkers-Tracing the molecular function and clinical implication. Cell Prolif. 2019;52(3):e12589. doi:10.1111/cpr.2019.52.issue-330873683
   PubMed Web of Science ®Google Scholar
• Wu Z, Yang Z, Dai Y, Zhu Q, Chen LA. Update on liquid biopsy in clinical management of non-small cell lung cancer. Onco Targets Ther. 2019;12:5097–5109. doi:10.2147/OTT.S20307031303765
   PubMed Web of Science ®Google Scholar
• Leers MPG. Circulating tumor DNA and their added value in molecular oncology. Clin Chem Lab Med. 2019. doi:10.1515/cclm-2019-0436
   Web of Science ®Google Scholar
• Wu TH, Hsiue EH, Yang JC. Opportunities of circulating tumor DNA in lung cancer. Cancer Treat Rev. 2019;78:31–41. doi:10.1016/j.ctrv.2019.07.00231326635
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Lee M, Jeffrey SS. Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clin Cancer Res. 2015;21(21):4786–4800. doi:10.1158/1078-0432.CCR-14-119026527805
   PubMed Web of Science ®Google Scholar
• Scilla KA, Rolfo C. The role of circulating tumor DNA in lung cancer: mutational analysis, diagnosis, and surveillance now and into the future. Curr Treat Options Oncol. 2019;20(7):61. doi:10.1007/s11864-019-0653-231203467
   PubMed Web of Science ®Google Scholar
• Moon DH, Lindsay DP, Hong S, Wang AZ. Clinical indications for, and the future of, circulating tumor cells. Adv Drug Deliv Rev. 2018;125:143–150. doi:10.1016/j.addr.2018.04.00229626548
   PubMed Web of Science ®Google Scholar
• Micalizzi DS, Maheswaran S, Haber DA. A conduit to metastasis: circulating tumor cell biology. Genes Dev. 2017;31:1827–1840. doi:10.1101/gad.305805.11729051388
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann Oncol. 2014;25(12):2304–2313. doi:10.1093/annonc/mdu48025336116
   PubMed Web of Science ®Google Scholar
• Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016;126(4):1208–1215. doi:10.1172/JCI8113527035812
   PubMed Web of Science ®Google Scholar
• Ruivo CF, Adem B, Silva M, Melo SA. The biology of cancer exosomes: insights and new perspectives. Cancer Res. 2017;77(23):6480–6488. doi:10.1158/0008-5472.CAN-17-099429162616
   PubMed Web of Science ®Google Scholar
• Bjornetro T, Redalen KR, Meltzer S, et al. An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer. J Extracell Vesicles. 2019;8(1):1567219. doi:10.1080/20013078.2019.156721930728923
   PubMed Web of Science ®Google Scholar
• Zheng M, Hou L, Ma Y, et al. Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors. Mol Cancer. 2019;18(1):76. doi:10.1186/s12943-019-0999-x30940131
   PubMedGoogle Scholar
• Marcuello M, Vymetalkova V, Neves RPL, et al. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol Aspects Med. 2019;69:107–122. doi:10.1016/j.mam.2019.06.00231189073
   PubMed Web of Science ®Google Scholar
• Cui M, Wang H, Yao X, et al. Circulating MicroRNAs in Cancer: potential and Challenge. Front Genet. 2019;10:626. doi:10.3389/fgene.2019.0062631379918
   PubMed Web of Science ®Google Scholar
• Min L, Zhu S, Chen L, et al. Evaluation of circulating small extracellular vesicles derived miRNAs as biomarkers of early colon cancer: a comparison with plasma total miRNAs. J Extracell Vesicles. 2019;8(1):1643670. doi:10.1080/20013078.2019.164367031448068
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981. doi:10.1158/0008-5472.CAN-16-263428701486
   PubMed Web of Science ®Google Scholar
• Ramnarine VR, Kobelev M, Gibb EA, et al. The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. Eur Urol. 2019;76:546–559. doi:10.1016/j.eururo.2019.07.04031445843
   PubMed Web of Science ®Google Scholar
• Sole C, Arnaiz E, Manterola L, Otaegui D, Lawrie CH. The circulating transcriptome as a source of cancer liquid biopsy biomarkers. Semin Cancer Biol. 2019;58:100–108. doi:10.1016/j.semcancer.2019.01.00330684535
   PubMed Web of Science ®Google Scholar
• McBride DJ, Orpana AK, Sotiriou C, et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer. 2010;49(11):1062–1069. doi:10.1002/gcc.2081520725990
   PubMed Web of Science ®Google Scholar
• Board RE, Wardley AM, Dixon JM, et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat. 2010;120(2):461–467. doi:10.1007/s10549-010-0747-920107891
   PubMed Web of Science ®Google Scholar
• Chen Z, Feng J, Buzin CH, et al. Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer. PLoS One. 2009;4(9):e7220. doi:10.1371/journal.pone.000722019789704
   PubMed Web of Science ®Google Scholar
• Garcia-Foncillas J, Alba E, Aranda E, et al. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann Oncol. 2017;28(12):2943–2949. doi:10.1093/annonc/mdx50128945877
   PubMed Web of Science ®Google Scholar
• Kruger S, Heinemann V, Ross C, et al. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann Oncol. 2018;29(12):2348–2355. doi:10.1093/annonc/mdy41730346475
   PubMed Web of Science ®Google Scholar
• Krug AK, Enderle D, Karlovich C, et al. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Ann Oncol. 2018;29(3):700–706. doi:10.1093/annonc/mdx76529216356
   PubMed Web of Science ®Google Scholar
• Boeckx N, Op de Beeck K, Beyens M, et al. Mutation and methylation analysis of circulating tumor DNA can be used for follow-up of metastatic colorectal cancer patients. Clin Colorectal Cancer. 2018;17(2):e369–e379. doi:10.1016/j.clcc.2018.02.00629605591
   PubMed Web of Science ®Google Scholar
• Guan Y, Mayba O, Sandmann T, et al. High-throughput and sensitive quantification of circulating tumor DNA by microfluidic-based multiplex PCR and next-generation sequencing. J Mol Diagn. 2017;19(6):921–932. doi:10.1016/j.jmoldx.2017.08.00128867605
   PubMed Web of Science ®Google Scholar
• Fredebohm J, Mehnert DH, Lober AK, et al. Detection and quantification of KIT mutations in ctDNA by plasma safe-SeqS. Adv Exp Med Biol. 2016;924:187–189.27753042
   PubMed Web of Science ®Google Scholar
• Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra168. doi:10.1126/scitranslmed.3003726
   Web of Science ®Google Scholar
• Iwahashi N, Sakai K, Noguchi T, et al. A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: a case report. Oncol Lett. 2018;16(5):6431–6436. doi:10.3892/ol.2018.946730405780
   PubMed Web of Science ®Google Scholar
• Demuth C, Winther-Larsen A, Madsen AT, Meldgaard P, Sorensen BS. A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. Oncotarget. 2018;9(57):31066–31076. doi:10.18632/oncotarget.v9i5730123427
   PubMedGoogle Scholar
• Sung JS, Chong HY, Kwon NJ, et al. Detection of somatic variants and EGFR mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction. Oncotarget. 2017;8(63):106901–106912. doi:10.18632/oncotarget.2245629290998
   PubMedGoogle Scholar
• Chen X, Chang CW, Spoerke JM, et al. Low-pass whole-genome sequencing of circulating cell-free DNA demonstrates dynamic changes in genomic copy number in a squamous lung cancer clinical cohort. Clin Cancer Res. 2019.
   Web of Science ®Google Scholar
• Mayrhofer M, De Laere B, Whitington T, et al. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Med. 2018;10(1):85. doi:10.1186/s13073-018-0595-530458854
   PubMedGoogle Scholar
• Jin CE, Koo B, Lee TY, et al. Simple and low-cost sampling of cell-free nucleic acids from blood plasma for rapid and sensitive detection of circulating tumor DNA. Adv Sci. 2018;5(10):1800614. doi:10.1002/advs.v5.10
   Web of Science ®Google Scholar
• Jimenez I, Chicard M, Colmet-Daage L, et al. Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis. Int J Cancer. 2019;144(1):68–79. doi:10.1002/ijc.v144.129923174
   PubMed Web of Science ®Google Scholar
• Chicard M, Colmet-Daage L, Clement N, et al. Whole-exome sequencing of cell-free DNA reveals temporo-spatial heterogeneity and identifies treatment-resistant clones in neuroblastoma. Clin Cancer Res. 2018;24(4):939–949. doi:10.1158/1078-0432.CCR-17-158629191970
   PubMed Web of Science ®Google Scholar
• Li C, Liu H, Zhang B, et al. Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors. J Cancer Res Clin Oncol. 2018;144(6):1079–1086. doi:10.1007/s00432-018-2634-429616327
   PubMed Web of Science ®Google Scholar